|Bid||0.00 x 2900|
|Ask||0.00 x 2200|
|Day's range||8.26 - 8.79|
|52-week range||6.88 - 33.79|
|Beta (5Y monthly)||0.76|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investors need to pay close attention to Inovio (INO) stock based on the movements in the options market lately.
In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss why Inovio Pharmaceuticals' (NASDAQ: INO) technology may result in a longer timeline to commercialization. Corinne Cardina: I have a question for you about the Inovio device. Do you think that this delivery device puts Inovio at a disadvantage compared to vaccines that do not require a device?
There are many ways to examine a stock's potential. Players predict which stocks will outperform or underperform the S&P 500 over a particular time frame. It also rates each stock according to the number of players who say it will beat the S&P 500.